



Commentator & Affiliation	Section	Comment	Response
Peer Reviewer #7	Executive Summary	p.6 L-42 replace , with a period	Changed ES-5
Peer Reviewer #7	Executive Summary	p. 7 L-6 ...or in part...	Changed prior to PR comments ES-8
Peer Reviewer #7	Executive Summary	...report 'few adverse events' was jarring and oversimplified but the statement following it brought more balance!	No response required
Peer Reviewer #7	Executive Summary	p. 8 guanfacine is a generic name and should not be capitalized. Statement on tolerance and improved by concurrent administration of a psycho-stimulant is not a statement worthy of inclusion in an Executive Summary, in my opinion. Why assume guanfacine should be continued rather than switched to a more effective, better established drug, namely, a stimulant? Endorsing off-label concomitant use in a general summary may not be wise as there is so little knowledge of safety of combinations either short- or long-term.	"guanfacine" corrected as necessary on ES-10 and p52 as per comment 10 th Jan 2010 Conclusion about Guanfacine clarified Table2, p14
Peer Reviewer #7	Executive Summary	p. 8 L-22 The statement on long periods of time is not shown in most community treatment empirical analyses of claims data. Perhaps, the term "relatively" and from follow up studies. But even so, MTA late data are not too supportive of long-term benefits.	ES-10 10 added "relatively"
Peer Reviewer #7	Executive Summary	p8 L-33 ...in combination with...	Now 10; Changed to 'and' as per other reviewer
Peer Reviewer #7	Executive Summary	p8 L-32 this paragraph and remainder of the exec summary have no references—they would be helpful as many readers do not get to read beyond the summary.	Citations with footnotes added to executive summary ES-1 to ES-16

